Cargando…

A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France

BACKGROUND: Comparative effectiveness and cost-effectiveness data for induction–maintenance (I–M) sequences for the treatment of patients with nonsquamous non-small-cell lung cancer (nsqNSCLC) are limited because of a lack of direct evidence. This analysis aimed to compare the cost-effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taipale, Kaisa, Winfree, Katherine B, Boye, Mark, Basson, Mickael, Sleilaty, Ghassan, Eaton, James, Evans, Rachel, Chouaid, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566359/ https://www.ncbi.nlm.nih.gov/pubmed/28860832 http://dx.doi.org/10.2147/CEOR.S128371

Ejemplares similares

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Zinner, Ralph G., et al.
Publicado: (2015)

Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France
por: Atsou, Kokuvi, et al.
Publicado: (2016)

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
por: Vergnenègre, Alain, et al.
Publicado: (2012)

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
por: Chouaïd, Christos, et al.
Publicado: (2014)

Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer
por: Zheng, Zhiwei, et al.
Publicado: (2022)

Cost analysis of adverse events associated with non-small cell lung cancer management in France
por: Chouaid, Christos, et al.
Publicado: (2017)

Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non–Small Cell Lung Cancer in the United States
por: Criss, Steven D., et al.
Publicado: (2019)

The association between asthma control, health care costs, and quality of life in France and Spain
por: Doz, Marianne, et al.
Publicado: (2013)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
por: Hofman, Véronique, et al.
Publicado: (2022)

Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
por: Pignata, Maud, et al.
Publicado: (2017)

The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta-Analysis
por: Li, Duo, et al.
Publicado: (2023)

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
por: Basson, Mickael, et al.
Publicado: (2017)

Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives
por: Aoun, Mabel, et al.
Publicado: (2022)

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
por: Borget, Isabelle, et al.
Publicado: (2014)

Transcriptomic analysis of preovipositional embryonic arrest in a nonsquamate reptile (Chelonia mydas)
por: Gárriz, Angela, et al.
Publicado: (2022)

Correction: Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives
por: Aoun, Mabel, et al.
Publicado: (2022)

Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China
por: Qiao, Liu, et al.
Publicado: (2021)

The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
por: Yang, James Chin-Hsin, et al.
Publicado: (2015)

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study
por: Molife, Cliff, et al.
Publicado: (2023)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
por: Rahimi, Siavash, et al.
Publicado: (2017)

Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
por: Luo, Xia, et al.
Publicado: (2022)

Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China
por: Chen, Ting, et al.
Publicado: (2022)

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
por: Walleser, Silke, et al.
Publicado: (2012)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
por: Velcheti, Vamsidhar, et al.
Publicado: (2021)

Current process and future path for health economic assessment of pharmaceuticals in France
por: Toumi, Mondher, et al.
Publicado: (2015)

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2014)

Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer
por: Shi, Yafei, et al.
Publicado: (2023)

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment
por: Toumi, Mondher, et al.
Publicado: (2017)

Factors associated with excessively lengthy treatment of tuberculosis in the eastern Paris region of France in 2004
por: Valin, Nadia, et al.
Publicado: (2010)

Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy
por: Pöhlmann, J., et al.
Publicado: (2020)

Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined
por: Chouaïd, Christos, et al.
Publicado: (2020)

Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary Disease
por: Atsou, Kokuvi, et al.
Publicado: (2011)

Analysis of COVID-19 inpatients in France during first lockdown of 2020 using explainability methods
por: Excoffier, Jean-Baptiste, et al.
Publicado: (2022)

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN)(†)
por: Obasaju, C., et al.
Publicado: (2013)

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study
por: Jiang, Qian, et al.
Publicado: (2019)

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study
por: Zhang, Jie, et al.
Publicado: (2021)

A Trial-Based Cost-Effectiveness Analysis of Erlotinib Alone versus Platinum-Based Doublet Chemotherapy as First-Line Therapy for Eastern Asian Nonsquamous Non–Small-Cell Lung Cancer
por: Wang, Siying, et al.
Publicado: (2013)

Hospital admissions and mortality for acute exacerbations of COPD during the COVID-19 pandemic: A nationwide study in France
por: Poucineau, Jonas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gm40eccnmh1r8i6d4d7fr4771d